Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Affymetrix Sued over Pending eBioscience Deal; Firm Pushes Back Acquisition Date

Affymetrix Sued over Pending eBioscience Deal; Firm Pushes Back Acquisition Date

Jan 03, 2012
Premium

Affymetrix is facing a lawsuit related to its imminent purchase of eBioscience. The firm has also pushed back the anticipated completion period for the deal, but said that the delay is not related to the new suit.

Tang Capital Partners, a San Diego-based investment fund, on Dec. 29, 2011, filed class action litigation in the Superior Court of California in the County of Santa Clara, Affy said last week in a filing with the US Securities and Exchange Commission.

The court does not make civil case documents available online.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Early Trial Responses

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Hurdles to Genomic Surveillance

Nature News writes that viral genomic surveillance in the US faces systemic issues.

Boosts Requested

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

PLOS Papers on Chronic Pain, Indigenous Populations in Mexico, SARS-CoV-2 Mutations

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

May
05
Featured Webinar

Establishing a Pharmacogenomic Service for Routine Clinical Care

Sponsored by
Illumina

Adverse drug reactions (ADRs) are responsible for around 5 percent of hospital admissions and occur in 6 percent to 15 percent of hospital stays.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.